Hemophilia APhase 4JOIN-usNCT05856266
An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
A Phase 4 study testing Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS) in people with Hemophilia A and Hemophilia B, run by Swedish Orphan Biovitrum at 56 sites in 11 countries.
Trial summary
The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc. Read more about this study
- Who is it for?
- Ages 6 years and older
- Conditions the study is for
- Hemophilia A, Hemophilia B
- What is being tested?
- Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 56 sitesin 11 countries
- Study dates
- 24 Aug 2023to 6 Dec 2023
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age ≥ 6 years
- Diagnosis of haemophilia A or B
- Having at least 6 months documented pre-study treatment data regarding treatment prescriptions and bleeding episodes prior to the baseline visit
- Previous treatment for haemophilia A or B with any marketed recombinant and/or plasma-derived FVIII or FIX concentrate for at least 6 months
- Start of prophylactic treatment with rFVIIIFc or rFIXFc prior to study enrollment or latest at the baseline visit, in accordance with local regulations
- Signed and dated informed consent provided by the patient, or the patient's legally authorized representative for patients under the legal age. Assent should be obtained from paediatric patients in accordance with local regulations
Who cannot join
- Any medical condition which in the opinion of the investigator makes the subject patient unsuitable for inclusion
- Prophylactic treatment with non-factor therapy during the 6 months prior to enrolment
- Presence of factor VIII or FIX inhibitory antibodies (inhibitors) (≥0.60 Bethesda Units [BU]/mL) at the latest available inhibitor test
- Enrolment in a concurrent clinical interventional study, or intake of an IMP, within three months prior to inclusion in this study
- Foreseeable inability to cooperate with given instructions or study procedures
Trial locations and contacts
56 sites in 11 countries.
56 sites in 11 countries
France20 sites
Study site 115
Bordeaux
Study site 129
Caen
Study site 125
Chambéry
Study site 110
Clermont-Ferrand
Study site 123
Dijon
Study site 124
Lille
Study site 111
Lyon
Study site 126
Marseille
Study site 120
Nancy
Study site 121
Nantes
Study site 113
Nîmes
Study site 119
Paris
Study site 130
Paris
Study site 118
Poitiers
Study site 117
Reims
Sudy site 122
Rennes
Study site 109
Rouen
Study site 112
Strasbourg
Study site 128
Toulouse
Study site 114
Tours
Spain10 sites
Study site 151
A Coruña
Study site 150
Alicante
Study site 152
Barcelona
Study site 149
Madrid
Study site 154
Málaga
Study site 156
Oviedo
Study site 153
Salamanca
Study site 157
Valencia
Study site 155
Valladolid
Study site 158
Zaragoza
Italy7 sites
Study site 136
Bologna
Study site 134
Brescia
Study site 138
Catania
Study site 140
Milan
Study site 137
Palermo
Study site 135
Pisa
Study site 139
Vicenza
Czechia5 sites
Study site 108
Brno
Study site 107
Liberec
Study site 104
Olomouc
Study site 105
Prague
Study site 106
Prague
Romania5 sites
Study site 145
Baia Mare
Study site 141
Bucharest
Study site 143
Craiova
Study site 146
Iași
Study site 142
Timișoara
About this study
Official title: An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.
The main question it aims to answer is the:
Read more
- Evaluation of the overall joint status as detected by ultrasound in haemophilia A and B patients treated with rFVIIIFc or rFIXFc prophylaxis over the 18-month study period.
Participants will come to 6-monthly visits during the 18-month long study period and will perform an ultrasound with the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol at each visit. At baseline and end of study visits, the patients will be assessed with the clinical scoring system Haemophilia Joint Health Score (HJHS) and complete patient questionnaires. Retrospective data from patient medical records will also be collected for at least 6 months before enrolment in the study.
Read the detailed description
The main purpose of this study is to prospectively describe the joint health over an 18-month period of prophylactic treatment with rFVIIIFc or rFIXFc in patients with haemophilia A or haemophilia B in a real-world setting in Europe.
This is a low-interventional, multicentre study using point-of-care US examination for regular monitoring of joint health and detection of hypertrophic synovium, cartilage and bone damage. At the same time, clinical joint status will also be examined by HJHS. This study will evaluate the presence, resolution, recurrence, and new development of target joints. It will also describe bleeding episodes and evaluate the quality of life and physical activity with PROs. If patients are using the CE marked Florio HAEMO app in their routine clinical practice, they will be offered to participate in an optional sub-study that aims to explore possible correlations between the levels of physical activity, the estimated FVIII/FIX levels and bleeding occurrence.
- Conditions
- Hemophilia A, Hemophilia B
- Being tested
- Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Haemophilia Joint Health Score (HJHS)
- Keywords
- Blood coagulation disorder, Coagulation protein disorder, Haemophilia, FVIII, FIX, Efmoroctocog alfa, Eftrenonacog alfa
- Medical subject headings
- Hemophilia A, Hemophilia B, Blood Coagulation Disorders, Coagulation Protein Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)Procedure or surgery
Ultrasound examination
Haemophilia Joint Health Score (HJHS)Other
Functional joint examination
| Study group | Role | What they receive |
|---|---|---|
| Efmoroctocog alfa or eftrenonacog alfa | Other | Efmoroctocog alfa or eftrenonacog alfa is prescribed and used according to usual clinical practice. Receives: Procedure: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Other: Haemophilia Joint Health Score (HJHS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS)
HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.
The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). The specific joint score is made up of three item scores: disease activity (synovitis), disease damage of articular surfaces, and disease damage of subchondral bone. The specific joint score is the sum of the three item scores for each specific joint. Its values range from 0 (minimum) to 8 (maximum). The total score represents the sum of item scores for abnormalities detected.
Measured: Baseline and month 18
Secondary outcomes (14)
Change From Baseline in HEAD-US Score for Hypertrophic Synovium
HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.
The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). The disease activity (synovitis) score rates the status of the hypertrophic synovium. Hypertrophic synovium is graded in three steps (0: absent/minimal; 1: mild/moderate [score=1], 2: severe [score=2]) based on the comprehensive evaluation of the joint recesses and the mean amount of synovial tissue contained in them.
Measured: Baseline, month 6, 12 and 18
Change From Baseline in HEAD-US Score for Cartilage
HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.
The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). Concerning the articular cartilage, the damage is graded in five steps (0: normal; 1: echotexture abnormalities and focal loss involving <25% of the target surface [score=1]; 2: partial/full-thickness loss of the cartilage involving at least 50% of the target surface [score=2]; 3: partial/full-thickness loss of the cartilage involving >50% of the target surface [score=3]; 4: complete cartilage destruction or absent visualization of the articular cartilage on the target surface [score=4]).
Measured: Baseline, month 6, 12 and 18
Change From Baseline in HEAD-US Score for Bone
HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.
The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). Damage of subchondral bone is scored using a three-grade scale (0: normal; 1: mild irregularities of the subchondral bone with/without initial osteophytes around the joint [score=1]; 2: deranged subchondral bone with/without erosions and presence of prominent osteophytes around the joint [score=2]).
Measured: Baseline, month 6, 12 and 18
Change From Baseline in Total Hemophilia Joint Health Score (HJHS) at Month 18 (EOS)
The HJHS measures joint health, in the domain of body structure and function (i.e., impairment). The six index joints (elbows, knees, and ankles) will be examined and scored. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits.
The total score will be the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease).
Measured: Baseline and month 18
Number of Target Joints
A target joint is defined as a joint with three or more spontaneous bleeds into the joint within a consecutive 6-month period. The study will evaluate the presence, resolution, recurrence, and new development of target joints.
Measured: Baseline, month 6, 12 and 18
Location of Target Joints
A target joint is defined as a joint with three or more spontaneous bleeds into the joint within a consecutive 6-month period. The study will evaluate the presence, resolution, recurrence, and new development of target joints.
Measured: Baseline, month 6, 12 and 18
Total Annualized Bleeding Rate (ABR)
For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location (e.g., muscle, joint, other), date of bleeding episode, dose (IU) and number of injections used to treat the bleed.
Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Joint ABR
For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location, date of bleeding episode, dose (IU) and number of injections used to treat the bleed.
Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Target Joint ABR
For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location, date of bleeding episode, dose (IU) and number of injections used to treat the bleed.
Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Traumatic/Spontaneous ABR
For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location (e.g., muscle, joint, other), date of bleeding episode, dose (IU) and number of injections used to treat the bleed.
Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
PROMIS Physical Function/Activity Short Form 6b and 8a Scores
Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures for adults (6b) consist of a single item rating physical function on average over the past 7 days, ranging from 5 (without any difficulty) to 1 (unable to do). Lower scores mean a worse outcome.
The Numeric Rating Scale measures for pediatric and parent proxy (8a) each consist of a single item rating physical activity on average over the past 7 days, ranging from 1 (no days) to 5 (6-7 days). Lower scores mean a worse outcome.
Measured: Baseline and 18 months
PROMIS Pain Intensity 3a and 1a Scores
Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures for adults (3a) consist of a single item rating pain over the past 7 days from 1 (had no pain) to 5 (very severe). Higher scores mean a worse outcome. The Numeric Rating Scale measures for pediatric and parent proxy (1a) each consist of a single item rating pain over the past 7 days, ranging from 0 (no pain) to 10 (worst pain you can think of). Higher scores mean a worse outcome.
Measured: Baseline and month 18
PROMIS Pain Interference Short Form 6a and 8a Scores
Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures (adult, pediatric, parent proxy) each consist of a single item rating pain interference with different activities over the past 7 days, ranging from 1 (not at all/never) to 5 (very much/almost always). Higher scores mean a worse outcome.
Measured: Baseline and month 18
IPAQ-SF Scores
International Physical Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week, as well as categorization into high, moderate, or low physical activity level. Higher scores mean higher physical activity level (better outcome).
Measured: Baseline and month 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2023
- Study start24 Aug 2023
- Primary completion6 Dec 2023
- Study completion6 Dec 2023
Why it stopped: The Sponsor has decided to stop the phase 4 study Sobi.HAEM89-007 (JOIN-us) due to a realignment of its development activities. The clinical trial hasn't been terminated due to a change in the benefit-risk balance.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Hemophilia AStudies of the same condition, open and under way.
- More trials run by Swedish Orphan BiovitrumThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a low-interventional study, with the drugs being prescribed and used according to clinical practice. The interventions in the study are the addition of the mandatory joint examinations HEAD-US (ultrasound) and HJHS (functional joint assessment).
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Swedish Orphan Biovitrum
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- IQVIA Pvt. Ltd
- Responsible party
- Sponsor
- Investigators
- Stefan Lethagen, MD, PhD, Study director, Swedish Orphan Biovitrum AB (publ)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05856266
- Sponsor's protocol ID
- Sobi.HAEM89-007
- Other IDs
- 2022-502921-16-00
- Acronym
- JOIN-us
- Status last verified
- Jan 2025
- First submitted
- 24 Apr 2023
- Last updated
- 16 Jan 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
- ClinicalTrials.gov ID
- NCT05856266
- Acronym / sponsor ID
- JOIN-us / Sobi.HAEM89-007
- Conditions
- Hemophilia A, Hemophilia B
- Keywords
- Blood coagulation disorder, Coagulation protein disorder, Haemophilia, FVIII, FIX, Efmoroctocog alfa, Eftrenonacog alfa
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The Sponsor has decided to stop the phase 4 study Sobi.HAEM89-007 (JOIN-us) due to a realignment of its development activities. The clinical trial hasn't been terminated due to a change in the benefit-risk balance.
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Swedish Orphan BiovitrumIndustry (pharma, biotech, devices)
- Collaborators
- IQVIA Pvt. Ltd
- Study start
- 24 Aug 2023 (actual)
- Primary completion
- 6 Dec 2023 (actual)
- Study completion
- 6 Dec 2023 (actual)
- First posted
- 12 May 2023 (actual)
- Results
- Posted 16 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.
The main question it aims to answer is the:
- Evaluation of the overall joint status as detected by ultrasound in haemophilia A and B patients treated with rFVIIIFc or rFIXFc prophylaxis over the 18-month study period.
Participants will come to 6-monthly visits during the 18-month long study period and will perform an ultrasound with the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol at each visit. At baseline and end of study visits, the patients will be assessed with the clinical scoring system Haemophilia Joint Health Score (HJHS) and complete patient questionnaires. Retrospective data from patient medical records will also be collected for at least 6 months before enrolment in the study.
Detailed description
The main purpose of this study is to prospectively describe the joint health over an 18-month period of prophylactic treatment with rFVIIIFc or rFIXFc in patients with haemophilia A or haemophilia B in a real-world setting in Europe.
This is a low-interventional, multicentre study using point-of-care US examination for regular monitoring of joint health and detection of hypertrophic synovium, cartilage and bone damage. At the same time, clinical joint status will also be examined by HJHS. This study will evaluate the presence, resolution, recurrence, and new development of target joints. It will also describe bleeding episodes and evaluate the quality of life and physical activity with PROs. If patients are using the CE marked Florio HAEMO app in their routine clinical practice, they will be offered to participate in an optional sub-study that aims to explore possible correlations between the levels of physical activity, the estimated FVIII/FIX levels and bleeding occurrence.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a low-interventional study, with the drugs being prescribed and used according to clinical practice. The interventions in the study are the addition of the mandatory joint examinations HEAD-US (ultrasound) and HJHS (functional joint assessment).
| Arm | Type | Receives |
|---|---|---|
| Efmoroctocog alfa or eftrenonacog alfa | Other | Procedure: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Other: Haemophilia Joint Health Score (HJHS)Efmoroctocog alfa or eftrenonacog alfa is prescribed and used according to usual clinical practice. |
Who may qualify
- Ages
- 6 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (6 listed)
- Age ≥ 6 years
- Diagnosis of haemophilia A or B
- Having at least 6 months documented pre-study treatment data regarding treatment prescriptions and bleeding episodes prior to the baseline visit
- Previous treatment for haemophilia A or B with any marketed recombinant and/or plasma-derived FVIII or FIX concentrate for at least 6 months
- Start of prophylactic treatment with rFVIIIFc or rFIXFc prior to study enrollment or latest at the baseline visit, in accordance with local regulations
Key exclusion criteria (5 listed)
- Any medical condition which in the opinion of the investigator makes the subject patient unsuitable for inclusion
- Prophylactic treatment with non-factor therapy during the 6 months prior to enrolment
- Presence of factor VIII or FIX inhibitory antibodies (inhibitors) (≥0.60 Bethesda Units [BU]/mL) at the latest available inhibitor test
- Enrolment in a concurrent clinical interventional study, or intake of an IMP, within three months prior to inclusion in this study
- Foreseeable inability to cooperate with given instructions or study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)Ultrasound examination | Procedure or surgery | Efmoroctocog alfa or eftrenonacog alfa |
| Haemophilia Joint Health Score (HJHS)Functional joint examination | Other | Efmoroctocog alfa or eftrenonacog alfa |
Primary outcome
Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS)
Time frame: Baseline and month 18
HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints. The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). The specific joint score is made up of three item scores: disease activity (synovitis), disease damage of articular surfaces, and disease damage of subchondral bone. The specific joint score is the sum of the three item scores for each specific joint. Its values range from 0 (minimum) to 8 (maximum). The total score represents the sum of item scores for abnormalities detected.
14 secondary outcomes
Change From Baseline in HEAD-US Score for Hypertrophic Synovium
Time frame: Baseline, month 6, 12 and 18
Change From Baseline in HEAD-US Score for Cartilage
Time frame: Baseline, month 6, 12 and 18
Change From Baseline in HEAD-US Score for Bone
Time frame: Baseline, month 6, 12 and 18
Change From Baseline in Total Hemophilia Joint Health Score (HJHS) at Month 18 (EOS)
Time frame: Baseline and month 18
Number of Target Joints
Time frame: Baseline, month 6, 12 and 18
Location of Target Joints
Time frame: Baseline, month 6, 12 and 18
Total Annualized Bleeding Rate (ABR)
Time frame: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Joint ABR
Time frame: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Target Joint ABR
Time frame: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
Traumatic/Spontaneous ABR
Time frame: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period
PROMIS Physical Function/Activity Short Form 6b and 8a Scores
Time frame: Baseline and 18 months
PROMIS Pain Intensity 3a and 1a Scores
Time frame: Baseline and month 18
PROMIS Pain Interference Short Form 6a and 8a Scores
Time frame: Baseline and month 18
IPAQ-SF Scores
Time frame: Baseline and month 18
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Hemophilia A
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
Active, not recruitingObservational study
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Hemophilia A or B
RecruitingPhase 1/2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Hemophilia A
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
Hemophilia B
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stefan Lethagen, MD, PhD study director
Swedish Orphan Biovitrum AB (publ)
56 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS) in people with Hemophilia A and Hemophilia B, run by Swedish Orphan Biovitrum at 56 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 56 sites in France, Spain, Italy, Czechia, Romania and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS) (time frame: Baseline and month 18). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2025.